JP2016506931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506931A5 JP2016506931A5 JP2015555360A JP2015555360A JP2016506931A5 JP 2016506931 A5 JP2016506931 A5 JP 2016506931A5 JP 2015555360 A JP2015555360 A JP 2015555360A JP 2015555360 A JP2015555360 A JP 2015555360A JP 2016506931 A5 JP2016506931 A5 JP 2016506931A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- buffer
- agent
- present
- pharmacologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000872 buffer Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000012929 tonicity agent Substances 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000007951 isotonicity adjuster Substances 0.000 claims description 5
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756306P | 2013-01-24 | 2013-01-24 | |
| US61/756,306 | 2013-01-24 | ||
| PCT/US2014/013036 WO2014117010A2 (en) | 2013-01-24 | 2014-01-24 | Composition for ophthalmic administration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506931A JP2016506931A (ja) | 2016-03-07 |
| JP2016506931A5 true JP2016506931A5 (OSRAM) | 2017-03-02 |
| JP6351629B2 JP6351629B2 (ja) | 2018-07-04 |
Family
ID=50102221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555360A Expired - Fee Related JP6351629B2 (ja) | 2013-01-24 | 2014-01-24 | 点眼用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140206708A1 (OSRAM) |
| EP (1) | EP2948130B1 (OSRAM) |
| JP (1) | JP6351629B2 (OSRAM) |
| CA (1) | CA2898644A1 (OSRAM) |
| WO (1) | WO2014117010A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| CA3019349A1 (en) | 2016-04-14 | 2017-10-19 | Azura Ophthalmics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| CA3166357A1 (en) | 2020-01-10 | 2021-07-15 | Azura Ophthalmics Ltd. | Instructions for composition and sensitivity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1227128A (en) * | 1916-11-06 | 1917-05-22 | Ohio Blower Company | Conveying mechanism. |
| ZA815175B (en) * | 1980-08-01 | 1982-09-29 | Smith & Nephew Ass | Pharmaceutical composition |
| HU207222B (en) * | 1990-02-15 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing eyedrops containing primycin |
| BR9711406A (pt) * | 1996-09-20 | 1999-08-17 | Bausch & Lomb | Sistema e m-todo para reumidifica-Æo de lentes de contato e alivio da secura dos olhos |
| AU2001278779A1 (en) * | 2000-08-25 | 2002-03-04 | Senju Pharmaceutical Co. Ltd. | Aqueous suspension preparations |
| EP1418903A2 (en) * | 2001-04-23 | 2004-05-19 | The Board of Regents of the University of Texas System | Prostanoids augment ocular drug penetration |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| JP2011525388A (ja) * | 2008-06-24 | 2011-09-22 | キューエルティー プラグ デリバリー，インク． | 緑内障の併用治療 |
| CN102271915B (zh) * | 2008-11-04 | 2014-11-26 | 巴斯夫欧洲公司 | 复合箔作为氧化敏感性聚合物的包装材料的用途，包装氧化敏感性聚合物的方法以及含有所述复合箔的包装 |
| WO2011017178A1 (en) * | 2009-07-28 | 2011-02-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| JP2013535451A (ja) * | 2010-07-21 | 2013-09-12 | アルコン リサーチ， リミテッド | 増強された溶解度特徴を有する薬学的組成物 |
-
2014
- 2014-01-24 JP JP2015555360A patent/JP6351629B2/ja not_active Expired - Fee Related
- 2014-01-24 EP EP14704453.1A patent/EP2948130B1/en active Active
- 2014-01-24 WO PCT/US2014/013036 patent/WO2014117010A2/en not_active Ceased
- 2014-01-24 CA CA2898644A patent/CA2898644A1/en not_active Abandoned
- 2014-01-24 US US14/163,948 patent/US20140206708A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010266120B2 (en) | Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections | |
| JP2011527339A5 (OSRAM) | ||
| JP2009524692A (ja) | ドライアイのための処方物および方法 | |
| JP2015007136A5 (OSRAM) | ||
| JP2015110672A (ja) | ビマトプロストおよびブリモニジンの固定用量の組み合わせ | |
| JP2012520882A5 (OSRAM) | ||
| JP2013500977A5 (OSRAM) | ||
| JP2021102626A (ja) | ブリモニジン及びチモロールの固定用量合剤 | |
| JP2011093923A (ja) | 点眼剤 | |
| JP2015528501A5 (OSRAM) | ||
| TW202031263A (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP2016506931A5 (OSRAM) | ||
| CN107708738A (zh) | 含有柠檬酸酯的贮库制剂 | |
| WO2016171152A1 (ja) | 角膜障害の治療剤、改善剤または予防剤 | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina | |
| JP7599838B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
| JP4980226B2 (ja) | 眼科用組成物及びその使用方法 | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| Romanowski et al. | Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis | |
| EP2143422A1 (en) | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections | |
| TWI816660B (zh) | 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途 | |
| JP6474913B2 (ja) | 外用剤 | |
| WO2016020408A2 (en) | Compounds for preventing ototoxicity | |
| US20240261291A1 (en) | Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 |